Cargando…

Combination of the NRF2 Inhibitor and Autophagy Inhibitor Significantly Inhibited Tumorigenicity of Castration-Resistant Prostate Cancer

Prostate cancer (PCa) is the most frequent cancer in men. Developing new treatment methods for CRPC will be a significant challenge in the clinical treatment of PCa. In conclusion, the results of this study show that NRF2 is downregulated in untreated PCa samples compared to normal PCa samples; howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yong, Xin, Zhixiang, Dong, Baijun, Xue, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236814/ https://www.ncbi.nlm.nih.gov/pubmed/35770119 http://dx.doi.org/10.1155/2022/4182401

Ejemplares similares

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
por: Coulter, Jonathan B., et al.
Publicado: (2023)

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
por: Morra, Francesco, et al.
Publicado: (2017)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023)

PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer
por: Sha, Jianjun, et al.
Publicado: (2016)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
por: Sonnenburg, Daniel, et al.
Publicado: (2018)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone
por: Fan, Liancheng, et al.
Publicado: (2017)

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
por: Wu, Changping, et al.
Publicado: (2015)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
por: Luo, Yong, et al.
Publicado: (2018)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer
por: Ranasinghe, Weranja K B, et al.
Publicado: (2014)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
por: Kase, Adam M, et al.
Publicado: (2020)

Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells
por: Corno, Cristina, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2021)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

A catalase inhibitor: Targeting the NADPH-binding site for castration-resistant prostate cancer therapy
por: Cao, Ya Ya, et al.
Publicado: (2023)

Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
por: Chung, Doo Yong, et al.
Publicado: (2021)

Low Tumorigenic Response to 3,2′‐Dimethyl‐4‐aminobiphenyl Administration in the Prostate of Rats Castrated at Birth
por: Shirai, Tomoyuki, et al.
Publicado: (1988)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer
por: Bello, Thomas, et al.
Publicado: (2021)

Roles of autophagy in androgen-induced benign prostatic hyperplasia in castrated rats
por: Liu, Rong-Fu, et al.
Publicado: (2018)

A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo
por: Mi, Yuan-yuan, et al.
Publicado: (2023)

NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy
por: Etani, Toshiki, et al.
Publicado: (2019)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling
por: Lin, Chenchu, et al.
Publicado: (2021)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

MET inhibition enhances PARP inhibitor efficacy in castration‐resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways
por: Zhou, Sihai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ukgnqf548edup217u8efa7dasb